# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Presentation to include new patient-reported outcomes (PRO) data from the Phase 3 VERITAC-2 clinical trial
Pfizer Inc. (NYSE:PFE, "Pfizer"))) will present data across its infectious disease portfolio at the upcoming IDWeek 202...
https://www.youtube.com/watch?v=XOtOCzut9pM
Trump to announce new deal with AstraZeneca to lower prescription drug costs for Americans using most-favored-nation pricing mo...
Morgan Stanley analyst Terence Flynn maintains Pfizer (NYSE:PFE) with a Equal-Weight and lowers the price target from $33 to...
Pharmacies and GoodRx are in talks to join TrumpRx, a new drug pricing site aiming to lower prescription costs for U.S. consumers.
Amgen launches AmgenNow, offering Repatha at $239 per month, expanding direct access for U.S. patients with no insurer restrict...